EpiGuard has announced that the EpiShuttle has been approved by the Therapeutic Goods Administration (TGA) and is now available for use in the Australian market.

TGA is Australia’s regulatory authority for therapeutic goods such as medicines, medical devices, and diagnostic tests. 

This approval is a significant milestone for EpiGuard as it demonstrates that the EpiShuttle meets the high standards required by the Australian regulatory authorities. It allows us to expand our market presence and provide a valuable solution to healthcare providers in Australia. The EpiShuttle will be a valuable asset to medical providers, allowing them to transport infectious patients safely and efficiently in emergency situations.